<code id='873E0A485A'></code><style id='873E0A485A'></style>
    • <acronym id='873E0A485A'></acronym>
      <center id='873E0A485A'><center id='873E0A485A'><tfoot id='873E0A485A'></tfoot></center><abbr id='873E0A485A'><dir id='873E0A485A'><tfoot id='873E0A485A'></tfoot><noframes id='873E0A485A'>

    • <optgroup id='873E0A485A'><strike id='873E0A485A'><sup id='873E0A485A'></sup></strike><code id='873E0A485A'></code></optgroup>
        1. <b id='873E0A485A'><label id='873E0A485A'><select id='873E0A485A'><dt id='873E0A485A'><span id='873E0A485A'></span></dt></select></label></b><u id='873E0A485A'></u>
          <i id='873E0A485A'><strike id='873E0A485A'><tt id='873E0A485A'><pre id='873E0A485A'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:62
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Prior authorization reform is both possible and imperative
          Prior authorization reform is both possible and imperative

          AdobeImaginethisscene:Youareacancerpatientalreadynavigatingfearanduncertaintyaroundyourtreatment,whe

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

          Understandhowscience,healthpolicy,andmedicineshapetheworldeveryday.SignupforourMorningRoundsnewslett